venetoclax sold brand names venclexta venclyxto medication used treat adults chronic lymphocytic leukemia cll small lymphocytic lymphoma sll acute myeloid leukemia common side effects low levels neutrophils type white blood cell diarrhea nausea anemia low red blood cell counts nose throat infection venetoclax attaches protein called protein present high amounts cll cancer cells helps cells survive longer body makes resistant cancer attaching blocking actions venetoclax causes death cancer cells thereby slows progression us venetoclax indicated adults chronic lymphocytic leukemia cll small lymphocytic lymphoma indication depend mutation status e g deletion ighv mutation eu venetoclax monotherapy indicated treatment chronic lymphocytic leukemia cll presence deletion mutation adults unsuitable failed b cell receptor pathway inhibitor treatment cll absence deletion mutation adults failed chemoimmunotherapy b cell receptor pathway venetoclax also indicated part combination therapy acute myeloid leukemia purpose used azacitidine decitabine lowdose cytarabine newly diagnosed adults age years older health problems intensive chemotherapy common side effects venetoclax include neutropenia low white blood cell count nausea anemia diarrhea upper respiratory tract infection fatigue thrombocytopenia low platelet count major side effects include tumor lysis syndrome severe neutropenia additionally drug may cause fertility problems venetoclax venetoclax blocks antiapoptotic bcell protein leading programmed cell death cll cells overexpression lymphoid malignancies linked increased resistance maximum plasma concentration achieved oral administration occurred hours steady state maximum concentration lowfat meal conditions mg daily dose found μgml recommended venetoclax administered apparent volume distribution venetoclax approximately l highly bound human plasma protein within concentration range μm μgml fraction unbound plasma less venetoclax metabolized proven invitro using drug consume grapefruit products contain additionally using venetoclax recommended use drugs contain inhibitors ie erythromycin ciprofloxacin diltiazem dronedarone fluconazole venetoclax excreted body via fecal united states food drug administration fda granted breakthrough therapy designation venetoclax people cll sll relapsed become intolerant refractory previous treatmentmedical citation needed april fda approved venetoclax use cll deletion deletion located chromosome short arm treated least one prior based overall response rate indication approved accelerated fda efficacy venetoclax tested singlearm clinical trial participants cll deletion received least one prior trial participants took venetoclax orally every day beginning mg increasing fiveweek period results showed percent trial participants experienced complete partial remission trial conducted us canada france germany poland united kingdom application venetoclax granted priority review accelerated approval along breakthrough therapy designation orphan drug venetoclax approved use european union december june fda granted regular approval venetoclax people cll small lymphocytic lymphoma sll without deletion received least one prior approval based murano randomized multicenter openlabel trial venetoclax rituximab venr versus bendamustine rituximab br participants cll received least one prior line participants venr arm completed rampup venetoclax scheduleand received venetoclax mg daily months measured rituximab start rituximab initiated venetoclax rampup given cycles intravenously cycle day intravenously day cycles cycle comparator arm received cycles br bendamustine days cycle rituximab described dose application venetoclax combination rituximab granted priority review along breakthrough therapy november united states venetoclax approved combination azacitidine decitabine lowdose cytarabine treatment newly diagnosed acute myeloid leukemia aml adults age years older comorbidities preclude use intensive induction accelerated approval based two openlabel nonrandomized trials participants newly diagnosed aml years age comorbidities precluded use intensive induction efficacy established based rate complete remission cr cr study nonrandomized openlabel clinical trial venetoclax combination azacitidine decitabine newly diagnosed participants combination azacitidine participants achieved cr ci median observed time remission months range combination decitabine participants achieved cr ci median observed time remission months range observed time remission time start cr data cutoff date relapse phase study azacitidine venetoclax untreated acute myeloid leukemia eligible standard induction chemotherapy addition venetoclax azacitidine resulted improvement median overall survival months versus months improved complete remission study nonrandomized openlabel trial venetoclax combination lowdose cytarabine newly diagnosed participants aml including participants previous exposure hypomethylating agent antecedent hematologic combination lowdose cytarabine participants achieved cr ci median observed time remission months range may label extended accelerated approval include adults cllsll disregarding prior treatment mutation approval based randomized multicenter open label actively controlled trial venetoclax combination obinutuzumab veng versus obinutuzumab combination chlorambucil gclb participants previously untreated cll coexisting medical major efficacy outcome progressionfree survival pfs assessed independent review trial demonstrated statistically significant improvement pfs participants received veng compared received gclb hr ci median pfs reached either arm median followup duration overall response rate veng arm compared gclb arm trial also demonstrated statistically significant improvements rates minimal residual disease negativity less one cll cell per leukocytes bone marrow peripheral overall survival data mature fda used realtime oncology review assessment aid pilot program application granted priority review well orphan drug breakthrough therapy approval granted months ahead prescription drug user fee act pdufa abbvie inc manufactures marketed abbvie genentech usa member roche abbvie genentech commercializing drug within united states abbvie rights outside according reuters drugs watch forecast sales venetoclax competition well potential combination expected drugs ibrutinib idelalisib also approved treat venetoclax patented abbvie venetoclax tested treat hematological cancers including nonhodgkins lymphoma multiple myeloma diffuse large bcell lymphoma follicular june european hematology association eha annual congress abbvie roche announced results phase iii trial showed percent reduction risk death aml patients ineligible intensive chemotherapy treated venetoclax plus azacitidine compared azacitidine plus httpsenwikipediaorgwikivenetoclax